Tesamorelin
Growth hormone–releasing hormone (GHRH) analog
Quick Answer
A synthetic GHRH analog that, unlike most other GHRH-pathway peptides in this database, has gone through the full FDA drug-approval process for a specific indication.
Why People Are Interested
One of the few compounds in this library with a real FDA approval behind it, which makes it a useful reference point for what the strongest tier of evidence actually looks like — even though its approval is for a specific, narrow use, not general fat loss.
What People Hope It May Do
Broader body-composition and metabolic benefits beyond its approved indication (visceral fat in HIV-associated lipodystrophy), plus early curiosity about cognitive-research angles. (Commonly discussed or proposed — not an established, evidence-backed outcome unless separately stated in Human Evidence above.)
Potential / Research Areas
Effects on visceral fat in other populations beyond the currently approved indication
Metabolic and lipid-related outcomes
Potential cognitive-research applications (early-stage)
How It May Work
Stimulates the pituitary gland to release growth hormone via the natural GHRH receptor pathway.
What Human Research Shows
Supported by randomized controlled trials sufficient for FDA approval in its specific approved indication — a meaningfully stronger evidence tier than most compounds in this database, though narrower in approved scope than semaglutide/tirzepatide.
What Preclinical Research Shows
Standard preclinical pharmacology/toxicology package preceding its approved human trials.
Six independent readings, not one score. This reflects the volume and stage of research and discussion — it is not a rating of safety or effectiveness.
"Real-World Interest" and "Research Momentum" reflect the volume of public discussion and research activity Element Health Labs has observed — an editorial judgment, not a measured statistic, and not a claim about clinical significance. Anecdotal popularity is not evidence of effectiveness.
What People Report
What Experts Are Saying
Curated commentary specific to Tesamorelin is planned as the Expert & Creator Library grows. Being listed there does not imply an expert's endorsement of Element Health Labs.
Clinical Trials
For the current, authoritative list of registered trials involving Tesamorelin, search ClinicalTrials.gov directly — trial status changes frequently, and that registry is the source of truth, not a static summary on this page.
Potential Risks & Side Effects
Prescribing information includes indication-specific warnings and monitoring requirements. General information only — not individualized guidance; actual use requires a licensed provider familiar with the approved indication and the patient's specific history.
Regulatory Status
FDA-approved under the brand name Egrifta, specifically for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. This is a narrow, specific approval — it should never be generalized into a blanket "FDA-approved for fat loss" claim.
What We Still Don't Know
Whether its approved-indication results generalize to other populations, and what its early-stage cognitive-research signals actually mean, if anything, for broader use.
Limitations of Evidence
Evidence base is specific to the approved population (HIV-associated lipodystrophy); extrapolation to other populations or goals is not supported by the same evidence and should be labeled as such.
Keep Researching
- Search ClinicalTrials.gov for Tesamorelin
- Expert & Creator Library
- This Week in Peptides
- Understanding Your Bloodwork
- Related peptides:
Last reviewed: 2026-09-08 (Key studies/References backfilled and independently verified against live DailyMed labels)